PAVmed Inc. (NASDAQ:PAVM – Get Free Report) was the target of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 262,500 shares, a decline of 25.8% from the January 31st total of 354,000 shares. Currently, 2.7% of the shares of the company are sold short. Based on an average trading volume of 211,600 shares, the days-to-cover ratio is currently 1.2 days.
Wall Street Analysts Forecast Growth
Separately, Ascendiant Capital Markets reduced their price objective on PAVmed from $21.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, December 9th.
Institutional Investors Weigh In On PAVmed
PAVmed Stock Performance
Shares of NASDAQ:PAVM traded down $0.03 on Tuesday, hitting $0.66. The company’s stock had a trading volume of 94,556 shares, compared to its average volume of 102,852. PAVmed has a 12 month low of $0.57 and a 12 month high of $3.16. The company has a market capitalization of $7.31 million, a price-to-earnings ratio of -0.15 and a beta of 1.19. The stock’s 50-day moving average is $0.67 and its two-hundred day moving average is $0.93.
PAVmed Company Profile
PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.
See Also
- Five stocks we like better than PAVmed
- Ride Out The Recession With These Dividend Kings
- GitLab: Get In While It’s Down—Big Rebound Ahead
- What Does a Stock Split Mean?
- Tesla Stock: Finding a Bottom May Take Time
- What Are the FAANG Stocks and Are They Good Investments?
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.